In total, 85–90% of patients with de novo JMML harbor mutations in genes that regulate the Ras pathway: PTPN11 35%, NRAS/KRAS 30%, NF1 loss 10–15% [reviewed in Ref. This evidence concerns the gene NRAS and juvenile myelomonocytic leukemia.